Loading...
Exelixis, Inc.
EX9.DE•XETRA
Healthcare
Biotechnology
€32.28
€0.39(1.22%)
Exelixis, Inc. (EX9.DE) Financial Performance & Income Statement Overview
Review Exelixis, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
18.49%
↑ 18.49%
Operating Income Growth
253.82%
↑ 253.82%
Net Income Growth
150.89%
↑ 150.89%
Operating Cash Flow Growth
110.00%
↑ 110.00%
Operating Margin
27.88%
↑ 27.88%
Gross Margin
96.49%
↑ 96.49%
Net Profit Margin
24.04%
↑ 24.04%
ROE
23.78%
↑ 23.78%
ROIC
23.77%
↑ 23.77%
Exelixis, Inc. (EX9.DE) Income Statement & Financial Overview
Review Exelixis, Inc.'s (EX9.DE) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $566.75M | $539.54M | $637.18M | $425.23M |
| Cost of Revenue | $19.96M | $17.33M | $17.67M | $21.26M |
| Gross Profit | $546.79M | $522.21M | $619.51M | $403.97M |
| Gross Profit Ratio | $0.96 | $0.97 | $0.97 | $0.95 |
| R&D Expenses | $249.002M | $222.57M | $211.15M | $227.69M |
| SG&A Expenses | $134.33M | $111.80M | $132.01M | $113.98M |
| Operating Expenses | $383.58M | $386.14M | $343.16M | $341.67M |
| Total Costs & Expenses | $403.55M | $351.70M | $360.83M | $362.93M |
| Interest Income | $21.30M | $18.71M | $17.26M | $19.89M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $7.64M | $7.45M | $7.33M | $6.38M |
| EBITDA | $171.10M | $195.30M | $283.68M | $68.67M |
| EBITDA Ratio | $0.30 | $0.36 | $0.45 | $0.24 |
| Operating Income | $163.21M | $136.07M | $276.35M | $29.46M |
| Operating Income Ratio | $0.29 | $0.25 | $0.43 | $0.07 |
| Other Income/Expenses (Net) | $21.57M | $18.68M | $16.97M | $19.80M |
| Income Before Tax | $184.77M | $154.75M | $292.85M | $49.27M |
| Income Before Tax Ratio | $0.33 | $0.29 | $0.46 | $0.12 |
| Income Tax Expense | $44.91M | $36.78M | $66.73M | $11.95M |
| Net Income | $139.86M | $117.97M | $226.12M | $37.32M |
| Net Income Ratio | $0.25 | $0.22 | $0.35 | $0.09 |
| EPS | $0.48 | $0.41 | $0.78 | $0.12 |
| Diluted EPS | $0.47 | $0.40 | $0.77 | $0.12 |
| Weighted Avg Shares Outstanding | $290.03M | $285.62M | $289.22M | $300.76M |
| Weighted Avg Shares Outstanding (Diluted) | $296.13M | $291.48M | $293.97M | $305.53M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan